NCT00494234 - Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2007

Primary Completion Date

February 27, 2009

Study Completion Date

December 21, 2022

Conditions

Breast Neoplasms

Interventions

DRUG

Olaparib

Participants will receive capsules of olaparib orally as stated in arm description.

Trial Locations (17)

2031

Research Site, Randwick

3000

Research Site, Melbourne

24105

Research Site, Kiel

50937

Research Site, Cologne

81675

Research Site, München

90048

Research Site, West Hollywood

91010

Research Site, Duarte

6423906

Research Site, Tel Aviv

02115

Research Site, Boston

08907

Research Site, Hospitalet deLlobregat

08035

Research Site, Madrid

221 85

Research Site, Lund

CB2 0QQ

Research Site, Cambridge

EH4 2XR

Research Site, Edinburgh

SW3 6JJ

Research Site, Fulham

SE1 9RT

Research Site, London

M20 4BX

Research Site, Manchester